A citation-based method for searching scientific literature

Yoshihiro Yamamoto, Masashi Kanai, Tadayuki Kou, Aiko Sugiyama, Eijiro Nakamura, Hidehiko Miyake, Takahiro Yamada, Masakazu Nishigaki, Tomohiro Kondo, Hiromi Murakami, Masako Torishima, Shigemi Matsumoto, Shinji Kosugi, Manabu Muto. J Hum Genet 2020
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.
Ashton C Berger, Anil Korkut, Rupa S Kanchi, Apurva M Hegde, Walter Lenoir, Wenbin Liu, Yuexin Liu, Huihui Fan, Hui Shen, Visweswaran Ravikumar,[...]. Cancer Cell 2018
185
100

Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer.
Jasmeet Singh, Yelena Novik, Stacey Stein, Matthew Volm, Marlene Meyers, Julia Smith, Coral Omene, James Speyer, Robert Schneider, Komal Jhaveri,[...]. Breast Cancer Res 2014
43
100

ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data.
Kai Wang, Mingyao Li, Hakon Hakonarson. Nucleic Acids Res 2010
100

Clinical and Epidemiological Profile of Breast Cancer in Mexico: Results of the Seguro Popular.
Nancy Reynoso-Noverón, Cynthia Villarreal-Garza, Enrique Soto-Perez-de-Celis, Claudia Arce-Salinas, Juan Matus-Santos, María Teresa Ramírez-Ugalde, Alberto Alvarado-Miranda, Paula Cabrera-Galeana, Abelardo Meneses-García, Fernando Lara-Medina,[...]. J Glob Oncol 2017
19
100

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
Daniel P Silver, Andrea L Richardson, Aron C Eklund, Zhigang C Wang, Zoltan Szallasi, Qiyuan Li, Nicolai Juul, Chee-Onn Leong, Diana Calogrias, Ayodele Buraimoh,[...]. J Clin Oncol 2010
639
100


A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study.
E Alba, J I Chacon, A Lluch, A Anton, L Estevez, B Cirauqui, E Carrasco, L Calvo, M A Segui, N Ribelles,[...]. Breast Cancer Res Treat 2012
84
100

Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics.
Andrew Stone, Robert L Sutherland, Elizabeth A Musgrove. Crit Rev Oncog 2012
40
100

A new genome-driven integrated classification of breast cancer and its implications.
Sarah-Jane Dawson, Oscar M Rueda, Samuel Aparicio, Carlos Caldas. EMBO J 2013
175
100

Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial.
Mogens Bernsdorf, Christian Ingvar, Leif Jörgensen, Malgorzata K Tuxen, Erik H Jakobsen, Anna Saetersdal, Marie Louise Kimper-Karl, Niels Kroman, Eva Balslev, Bent Ejlertsen. Breast Cancer Res Treat 2011
47
100

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
M A Vollebergh, E H Lips, P M Nederlof, L F A Wessels, M K Schmidt, E H van Beers, S Cornelissen, M Holtkamp, F E Froklage, E G E de Vries,[...]. Ann Oncol 2011
115
100

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
Nadine M Tung, Mark E Robson, Steffen Ventz, Cesar A Santa-Maria, Rita Nanda, Paul K Marcom, Payal D Shah, Tarah J Ballinger, Eddy S Yang, Shaveta Vinayak,[...]. J Clin Oncol 2020
37
100

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Andrew Tutt, Mark Robson, Judy E Garber, Susan M Domchek, M William Audeh, Jeffrey N Weitzel, Michael Friedlander, Banu Arun, Niklas Loman, Rita K Schmutzler,[...]. Lancet 2010
100

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
Gunter von Minckwitz, Andreas Schneeweiss, Sibylle Loibl, Christoph Salat, Carsten Denkert, Mahdi Rezai, Jens U Blohmer, Christian Jackisch, Stefan Paepke, Bernd Gerber,[...]. Lancet Oncol 2014
468
100

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.
Eve T Rodler, Brenda F Kurland, Melissa Griffin, Julie R Gralow, Peggy Porter, Rosa F Yeh, Vijayakrishna K Gadi, Jamie Guenthoer, Jan H Beumer, Larissa Korde,[...]. Clin Cancer Res 2016
39
100

Revealing the Molecular Portrait of Triple Negative Breast Tumors in an Understudied Population through Omics Analysis of Formalin-Fixed and Paraffin-Embedded Tissues.
Felipe Vaca-Paniagua, Rosa María Alvarez-Gomez, Hector Aquiles Maldonado-Martínez, Carlos Pérez-Plasencia, Veronica Fragoso-Ontiveros, Federico Lasa-Gonsebatt, Luis Alonso Herrera, David Cantú, Enrique Bargallo-Rocha, Alejandro Mohar,[...]. PLoS One 2015
12
100

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.
Garrett M Frampton, Alex Fichtenholtz, Geoff A Otto, Kai Wang, Sean R Downing, Jie He, Michael Schnall-Levin, Jared White, Eric M Sanford, Peter An,[...]. Nat Biotechnol 2013
100

OncoKB: A Precision Oncology Knowledge Base.
Debyani Chakravarty, Jianjiong Gao, Sarah M Phillips, Ritika Kundra, Hongxin Zhang, Jiaojiao Wang, Julia E Rudolph, Rona Yaeger, Tara Soumerai, Moriah H Nissan,[...]. JCO Precis Oncol 2017
632
100


A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers.
Giandomenico Roviello, Manuela Milani, Angela Gobbi, Maria Rosa Cappelletti, Laura Zanotti, Chiara Senti, Alberto Bottini, Carla Strina, Sandra Sigala, Daniele Generali. Clin Breast Cancer 2016
4
100

Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts.
Katherine E Hutchinson, Susan E Yost, Ching-Wei Chang, Radia Marie Johnson, Adrian R Carr, Paul R McAdam, Daniel L Halligan, Chun-Chieh Chang, Daniel Schmolze, Jackson Liang,[...]. Clin Cancer Res 2020
20
100

Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.
Valgerdur Birgisdottir, Olafur A Stefansson, Sigridur K Bodvarsdottir, Holmfridur Hilmarsdottir, Jon G Jonasson, Jorunn E Eyfjord. Breast Cancer Res 2006
165
100

NCCN Guidelines Insights: Breast Cancer, Version 3.2018.
Matthew P Goetz, William J Gradishar, Benjamin O Anderson, Jame Abraham, Rebecca Aft, Kimberly H Allison, Sarah L Blair, Harold J Burstein, Chau Dang, Anthony D Elias,[...]. J Natl Compr Canc Netw 2019
87
100

ClinVar: improving access to variant interpretations and supporting evidence.
Melissa J Landrum, Jennifer M Lee, Mark Benson, Garth R Brown, Chen Chao, Shanmuga Chitipiralla, Baoshan Gu, Jennifer Hart, Douglas Hoffman, Wonhee Jang,[...]. Nucleic Acids Res 2018
815
100

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
100


Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Jeffrey N Weitzel, Susan L Neuhausen, Aaron Adamson, Shu Tao, Charité Ricker, Asaf Maoz, Margalit Rosenblatt, Bita Nehoray, Sharon Sand, Linda Steele,[...]. Cancer 2019
16
100



IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.
Mark Ayers, Jared Lunceford, Michael Nebozhyn, Erin Murphy, Andrey Loboda, David R Kaufman, Andrew Albright, Jonathan D Cheng, S Peter Kang, Veena Shankaran,[...]. J Clin Invest 2017
100

Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers.
Minjie Wei, Jinhua Xu, James Dignam, Rita Nanda, Lise Sveen, James Fackenthal, Tatyana A Grushko, Olufunmilayo I Olopade. Breast Cancer Res Treat 2008
67
100

A method and server for predicting damaging missense mutations.
Ivan A Adzhubei, Steffen Schmidt, Leonid Peshkin, Vasily E Ramensky, Anna Gerasimova, Peer Bork, Alexey S Kondrashov, Shamil R Sunyaev. Nat Methods 2010
100

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Ahmet Zehir, Ryma Benayed, Ronak H Shah, Aijazuddin Syed, Sumit Middha, Hyunjae R Kim, Preethi Srinivasan, Jianjiong Gao, Debyani Chakravarty, Sean M Devlin,[...]. Nat Med 2017
100

Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers.
Z Jin, G Tamura, T Tsuchiya, K Sakata, M Kashiwaba, M Osakabe, T Motoyama. Br J Cancer 2001
108
100

Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patients.
Hae Min Jeong, Ryong Nam Kim, Mi Jeong Kwon, Ensel Oh, Jinil Han, Se Kyung Lee, Jong-Sun Choi, Sara Park, Seok Jin Nam, Gyung Yup Gong,[...]. Oncotarget 2017
9
100

Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity.
Fernando Lara-Medina, Víctor Pérez-Sánchez, David Saavedra-Pérez, Monika Blake-Cerda, Claudia Arce, Daniel Motola-Kuba, Cynthia Villarreal-Garza, Ana Maria González-Angulo, Enrique Bargalló, Jose Luis Aguilar,[...]. Cancer 2011
127
100

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations.
David Tamborero, Carlota Rubio-Perez, Jordi Deu-Pons, Michael P Schroeder, Ana Vivancos, Ana Rovira, Ignasi Tusquets, Joan Albanell, Jordi Rodon, Josep Tabernero,[...]. Genome Med 2018
165
100

From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline.
Geraldine A Van der Auwera, Mauricio O Carneiro, Christopher Hartl, Ryan Poplin, Guillermo Del Angel, Ami Levy-Moonshine, Tadeusz Jordan, Khalid Shakir, David Roazen, Joel Thibault,[...]. Curr Protoc Bioinformatics 2013
100


Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
M L Telli, D G Stover, S Loi, S Aparicio, L A Carey, S M Domchek, L Newman, G W Sledge, E P Winer. Breast Cancer Res Treat 2018
16
100

T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells.
Tatyana Chtanova, Stuart G Tangye, Rebecca Newton, Nita Frank, Martin R Hodge, Michael S Rolph, Charles R Mackay. J Immunol 2004
532
100

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.
Bernard Pereira, Suet-Feung Chin, Oscar M Rueda, Hans-Kristian Moen Vollan, Elena Provenzano, Helen A Bardwell, Michelle Pugh, Linda Jones, Roslin Russell, Stephen-John Sammut,[...]. Nat Commun 2016
648
100


Integrative genomics viewer.
James T Robinson, Helga Thorvaldsdóttir, Wendy Winckler, Mitchell Guttman, Eric S Lander, Gad Getz, Jill P Mesirov. Nat Biotechnol 2011
100

Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer.
Xiaoxian Li, Jing Yang, Limin Peng, Aysegul A Sahin, Lei Huo, Kevin C Ward, Ruth O'Regan, Mylin A Torres, Jane L Meisel. Breast Cancer Res Treat 2017
124
100


IntOGen-mutations identifies cancer drivers across tumor types.
Abel Gonzalez-Perez, Christian Perez-Llamas, Jordi Deu-Pons, David Tamborero, Michael P Schroeder, Alba Jene-Sanz, Alberto Santos, Nuria Lopez-Bigas. Nat Methods 2013
320
100

Genomic landscape of adenoid cystic carcinoma of the breast.
Luciano G Martelotto, Maria R De Filippo, Charlotte K Y Ng, Rachael Natrajan, Laetitia Fuhrmann, Joanna Cyrta, Salvatore Piscuoglio, Huei-Chi Wen, Raymond S Lim, Ronglai Shen,[...]. J Pathol 2015
83
100

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.
Timothy A Yap, Li Yan, Amita Patnaik, Ivy Fearen, David Olmos, Kyriakos Papadopoulos, Richard D Baird, Liliana Delgado, Adekemi Taylor, Lisa Lupinacci,[...]. J Clin Oncol 2011
398
100

Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.
Matthew D Burstein, Anna Tsimelzon, Graham M Poage, Kyle R Covington, Alejandro Contreras, Suzanne A W Fuqua, Michelle I Savage, C Kent Osborne, Susan G Hilsenbeck, Jenny C Chang,[...]. Clin Cancer Res 2015
503
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.